Compare Danaher Corporation (DHR) vs Nebius Group NV (NBIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Nebius Group NV — how do they compare? Danaher Corporation trades at $220.7 (market cap $152.87B), while Nebius Group NV trades at $220.7 (market cap $59.73B). The key difference: Danaher Corporation is far larger — about 2.6× Nebius Group NV's market cap, and Danaher Corporation pays a 0.74% dividend while Nebius Group NV pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Nebius Group NV for 24 Days on average.
| DHR | NBIS | |
|---|---|---|
Market Cap | $152.87B | $59.73B |
Volume | 5,228,698 | 21,563,700 |
Sector | Health | Technology |
52-Week High | $242.05 | $286.69 |
52-Week Low | $161.91 | $73.87 |
Typical Hold Time | 69 Days | 24 Days |
Enterprise Value | $175.08B | $61.86B |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
NBIS trades at $220.95, down 6.8% on the day, with a bearish technical signal and high valuation ratios (P/E of 845.04). The company reported a net income of $82.50M in 2025, but recent quarterly EPS showed mixed results against expectations. Analyst consensus remains strongly bullish with a price target of $288.67, supported by significant revenue growth projections and strategic AI infrastructure deals.
The outlook for NBIS is clouded by high execution risks amid aggressive expansion, negative cash flow from investing, and insider selling. While analyst optimism and AI demand offer upside potential, investors face volatility from valuation concerns and competitive pressures in the cloud infrastructure sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →
